http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 23 Mar 2026 07:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/Press+Releases/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837 http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html <div class="xn-content"> <p class="prntac"><i>Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology </i></p><p class="prntac"><i>Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than <money>$16 billion</money> in worldwide sales </i></p><p><span class="legendSpanClass"><location value="LU/us.fl.tampa" idsrc="xmltag.org" >TAMPA, Fla.</location></span>, <span class="legendSpanClass"><chron>March 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:HURA" idsrc="xmltag.org" >TuHURA Biosciences, Inc.</span> (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, http://www.streetinsider.com/PRNewswire/Craig+Tendler%2C+M.D.%2C+JNJ%27s+Former+Global+Head+of+Oncology+Clinical+Development%2C+to+Lead+TuHURA+Bioscience%27s+VISTA+Program+in+AML+and+other+Blood+Related+Cancers/26200577.html Mon, 23 Mar 2026 07:45:00 -0400 A.08988233 A.13945385 A.31066700 A.39305831 A.40557829 A.50110018 A.50113931 A.60001765 HURA KTRA LEGN O.00170465 O.01845532 O.08640425 O.10076388 O.20738543 O.22422661 O.22949852 O.26498850 O.29384338 O.47731837